Oral Nirmatrelvir–Ritonavir for Covid-19 in Higher-Risk Outpatients
In two open-label trials, nirmatrelvir–ritonavir did not reduce the incidence of hospitalization or death among vaccinated higher-risk participants with SARS-CoV-2 infection.
Maternal RSV vaccination generates high-affinity antibodies that efficiently transfer to infants, providing enhanced passive immunity
These findings demonstrate that maternal RSV vaccination generates high-quality, affinity-matured transferable antibodies that provide passive immunity to infants.
Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective observational study
Real-world evidence on nirsevimab impact beyond the first season when given under universal immunisation programmes is emerging.
Effectiveness of long-acting monoclonal antibodies against laboratory-confirmed RSV in children aged 24 months and hospitalised for severe acute respiratory infection, European pilot study, 2024 to 2025
Passive immunisation with long-acting monoclonal antibodies (nirsevimab) targeting the two antigenic subgroups A and B of respiratory syncytial virus (RSV) was authorised by the European Medicines Agency for use in the European Union on 31 October 2022.
Clesrovimab for Prevention of RSV Disease in Healthy Infants
Clesrovimab is a long-acting investigational monoclonal antibody against site IV of the respiratory syncytial virus (RSV) fusion protein.
WHO EPI-WIN Webinar: Respiratory Syncytial Virus (RSV) genomic surveillance – how & why
Each year, RSV causes an estimated 3.6 million RSV-associated hospitalisations and approximately 100.000 RSV-attributable deaths in children under 5 years of age worldwide .
Influenza-Associated Acute Necrotizing Encephalopathy in US Children
The high morbidity and mortality emphasize the need for prevention, early recognition, intensive treatment, and standardized management protocols.
Comparative effectiveness of live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV) in children over multiple influenza seasons (2019–2023)
Annual vaccination with LAIV4 or IIV4 remains the best way to protect children against influenza infection.